Berkshire’s proxy, released Friday, restated the criteria that the company seeks in what will be its 13-member board.

Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced that Dr James Campbell will succeed Steven ...

Prescient Income Provider earns an Above Average Process Pillar rating. The largest contributor to the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the ...

Prescient Income Provider earns an Above Average Process Pillar rating. The primary contributor to the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the ...